GH Research PLC
SWB:1KA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
GH Research PLC
SWB:1KA
|
IE |
Intrinsic Value
The intrinsic value of GH Research PLC (1KA) under the Base Case is 3.59 EUR per share. Compared with the current market price of 15.165 EUR, the stock appears Overvalued by 76% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What GH Research Does
GH Research PLC is a clinical-stage biopharmaceutical company focused on mental health. It is developing inhaled drug candidates, led by GH001, for severe psychiatric conditions such as treatment-resistant depression. The company is not a drug seller today; its work is to run clinical studies, build the evidence needed for regulators, and move its compounds toward approval.
- Headquarters
- Ireland IE
- Employees
- 73
- IPO date
- Jun 25, 2021
Earnings Waterfall
GH Research PLC
The intrinsic value for GH Research PLC (1KA) under the Base Case is 3.59 EUR.
Compared with the current market price of 15.165 EUR, the stock appears Overvalued by 76% .